Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
Autore:
ODay, SJ; Gammon, G; Boasberg, PD; Martin, MA; Kristedja, TS; Guo, M; Stern, S; Edwards, S; Fournier, P; Weisberg, M; Cannon, M; Fawzy, NW; Johnson, TD; Essner, R; Foshag, LJ; Morton, DL;
Indirizzi:
St Johns Hlth Ctr, John Wayne Canc Inst, Div Med & Surg Oncol, Santa Monica, CA 90404 USA St Johns Hlth Ctr Santa Monica CA USA 90404 l, Santa Monica, CA 90404 USA
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 9, volume: 17, anno: 1999,
pagine: 2752 - 2761
SICI:
0732-183X(199909)17:9<2752:AOCBMB>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADVANCED MALIGNANT-MELANOMA; INTERFERON-ALPHA; PHASE-II; SEQUENTIAL CHEMOIMMUNOTHERAPY; DACARBAZINE CVD; ONCOLOGY-GROUP; CISPLATIN; CHEMOTHERAPY; THERAPY; COMBINATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: O'Day, SJ St Johns Hlth Ctr, John Wayne Canc Inst, Div Med Oncol, 2001 Santa Monica Blvd,Suite 1050W, Santa Monica, CA 90404 USA St Johns Hlth Ctr 2001 Santa Monica Blvd,Suite 1050W Santa Monica CA USA 90404
Citazione:
S.J. O'Day et al., "Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma", J CL ONCOL, 17(9), 1999, pp. 2752-2761

Abstract

Purpose: Concurrent biochemotherapy results in high response rates but also significant toxicity in patients with metastatic melanoma. We attempted ta improve its efficacy and decrease its toxicity by using decrescendo dosing of interleukin-2 (IL-2), posttreatment granulocyte colony-stimulating factor (G-CSF), and low-dose tamoxifen. Patients and Methods: Forty-five patients with poor prognosis metastatic melanoma were treated at a community hospital inpatient oncology unit affiliated with the John Wayne Cancer Institute (Santa Monica, CA) between July 1995 and September 1997. A 5-day modified concurrent biochemotherapy regimenof dacarbazine, vinblastine, cisplatin, decrescendo IL-2, interferon alfa-2b, and tamoxifen was repeated at 21-day intervals. G-CSF was administered beginning on day 6 for 7 to 10 days. Results: The overall response rate war 57% (95% confidence interval, 42% to 72%), the complete response rate was 23%, and the partial response rate was 34%. Complete remissions were achieved in an additional 11% of patients by surgical resection of residual disease after biochemotherapy. The mediantime to progression was 6.3 months and the median duration of survival was11.4 months. At a maximum follow-up of 36 months (range, 10 to 36 months),32% of patients are alive and 14% remain free of disease. Decrescendo IL-2dosing and administration of G-CSF seemed to reduce toxicity, length of hospital stay, and readmission rates. No patient required intensive care unitmonitoring, and there were no treatment-related deaths. Conclusion: The data from this study indicate that the modified concurrentbiochemotherapy regimen reduces the toxicity of concurrent biochemotherapywith no apparent decrease in response rate in patients with poor prognosismetastatic melanoma. (C) 1999 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 20:05:31